Claris Law Legal Blogging Community

Name:

E-mail:

Phone Number:

Zip Code:

Your Question:

Editor: Jamie Sheller
Profession: Trasylol Attorney

Category: Trasylol News

Bayer is pulling any remaining stock of Trasylol from the market after the final results of the BART study were published in the New England Journal of Medicine yesterday. Sales of the anti-bleeding drug were halted last year after preliminary results showed a fifty percent increase in death after its use. The drug still remained in inventory at some hospitals for use in cases that met strict guidelines.

The Food and Drug Administration said on Wednesday Bayer had notified the agency that it would begin removing remaining Trasylol stock from the U.S. market. Access will be limited to investigational use for certain patients who have no acceptable alternatives, the FDA said.

The FDA "supports Bayer's decision to completely remove Trasylol from regular use in the U.S. market," the agency said.

It is estimated that Trasylol caused thousands of deaths since it was approved. It was used during open heart bypass surgery and was responsible for kidney failure and heart failure. The patients involved in the BART study met the strict criteria for the drug's use but still had the higher rate of death.